Testing for COVID-19 is commanding the world's attention as uncertainties abound about the virus, its economic impact and how far to ease restrictions. And Abbott, with its seven COVID-19 tests available in the U.S. – including molecular, antigen and antibody tests – has emerged as a leading company helping develop important tests to detect the virus.1 All of these tests have been authorized by the U.S. Food and Drug Administration for Emergency Use Authorization. Testing is considered a key to helping slow the spread of COVID-19 and may play a role in reopening the economy. That's why Abbott is leveraging its diagnostics expertise and scale to develop more tests on more platforms, to help check millions of people around the world for COVID-19 and antibodies that help combat it. 'Demand for antigen tests exists and should be around for a very long time as we seek to get the virus under control and then be able to test, track, and isolate,' wrote William Blair analysts in a July 20 note.2 Want to know more? Get details on the differences between Abbott’s seven COVID-19 tests. And get a closer look at Abbott’s comprehensive efforts to tackle COVID-19. References 1Based on number of COVID-19 tests being distributed under FDA Emergency Use Authorization and CE Mark. 2William Blair, Diagnostics: Quidel Drops Friday Night 'Surprise' With New Sensitivity Data; Thoughts on Pooled Testing Announcement, July 20, 2020. This story was originally published on July 14, 2020. It was updated on August 26 to include reference to our announcement on Abbott's launch of its sixth COVID-19 test, a rapid antigen test, and a mobile app which displays antigen test results. It was further updated on November 11 to include references that Abbott received U.S. FDA emergency use authorization for its seventh COVID-19 test, an antibody IgM blood test.